In a regulatory filing, KalVista Pharmaceuticals CFO and CBO Benjamin Palleiko disclosed the sale of 40,855 common shares of the company on February 14 at a price of $15.0093 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KALV:
